

Stephen J Fuller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9401580/publications.pdf>

Version: 2024-02-01

43
papers

1,971
citations

279487

23
h-index

315357

38
g-index

43
all docs

43
docs citations

43
times ranked

2401
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1. <i>Journal of Immunology</i> , 2015, 195, 3665-3674.	0.4	219
2	Two haplotypes of the P2X ₇ receptor containing the Ala348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1 β secretion. <i>FASEB Journal</i> , 2010, 24, 2916-2927.	0.2	155
3	An Ile-568 to Asn Polymorphism Prevents Normal Trafficking and Function of the Human P2X7 Receptor. <i>Journal of Biological Chemistry</i> , 2003, 278, 17108-17113.	1.6	154
4	A Thr357 to Ser Polymorphism in Homozygous and Compound Heterozygous Subjects Causes Absent or Reduced P2X7 Function and Impairs ATP-induced Mycobacterial Killing by Macrophages. <i>Journal of Biological Chemistry</i> , 2006, 281, 2079-2086.	1.6	152
5	An Arg307 to Gln Polymorphism within the ATP-binding Site Causes Loss of Function of the Human P2X7 Receptor. <i>Journal of Biological Chemistry</i> , 2004, 279, 31287-31295.	1.6	125
6	P2X7 Receptor-Mediated Killing of an Intracellular Parasite, <i>Toxoplasma gondii</i> , by Human and Murine Macrophages. <i>Journal of Immunology</i> , 2010, 184, 7040-7046.	0.4	124
7	The Role of the P2X7 Receptor in Infectious Diseases. <i>PLoS Pathogens</i> , 2011, 7, e1002212.	2.1	121
8	Genetics of the P2X7 receptor and human disease. <i>Purinergic Signalling</i> , 2009, 5, 257-262.	1.1	114
9	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. <i>Blood</i> , 2007, 110, 3326-3333.	0.6	79
10	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemia—Susceptibility Loci. <i>American Journal of Human Genetics</i> , 2005, 77, 420-429.	2.6	65
11	Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. <i>European Journal of Human Genetics</i> , 2012, 20, 675-681.	1.4	63
12	Probenecid Blocks Human P2X7 Receptor-Induced Dye Uptake via a Pannexin-1 Independent Mechanism. <i>PLoS ONE</i> , 2014, 9, e93058.	1.1	63
13	A rare functional haplotype of the <i>P2RX4</i> and <i>P2RX7</i> genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration. <i>FASEB Journal</i> , 2013, 27, 1479-1487.	0.2	61
14	A 5 α 2 intronic splice site polymorphism leads to a null allele of the P2X7 gene in 1-2% of the Caucasian population. <i>FEBS Letters</i> , 2005, 579, 2675-2678.	1.3	55
15	Human Epidermal and Monocyte-Derived Langerhans Cells Express Functional P2X7 Receptors. <i>Journal of Investigative Dermatology</i> , 2005, 125, 482-490.	0.3	45
16	Dysregulation of the inflammatory response to the parasite, <i>Toxoplasma gondii</i> , in P2X7 receptor-deficient mice. <i>International Journal for Parasitology</i> , 2011, 41, 301-308.	1.3	35
17	Association of the 1513C polymorphism in the P2X7 gene with familial forms of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 125, 815-817.	1.2	31
18	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008, 111, 5691-5693.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X ₇ Receptor Antagonist. ACS Chemical Neuroscience, 2017, 8, 2374-2380.	1.7	30
20	A quantitative method for routine measurement of cell surface P2X ₇ receptor function in leucocyte subsets by two-colour time-resolved flow cytometry. Journal of Immunological Methods, 2007, 325, 67-77.	0.6	27
21	Lack of a Functioning P2X ₇ Receptor Leads to Increased Susceptibility to Toxoplasmic Ileitis. PLoS ONE, 2015, 10, e0129048.	1.1	27
22	Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. British Journal of Haematology, 2008, 142, 238-245.	1.2	26
23	Paroxetine suppresses recombinant human P2X ₇ responses. Purinergic Signalling, 2015, 11, 481-490.	1.1	26
24	A quantitative method for measuring innate phagocytosis by human monocytes using real-time flow cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 313-321.	1.1	24
25	New Insights into the Pathogenesis, Diagnosis, and Management of Mastocytosis. Hematology/Oncology Clinics of North America, 2012, 26, 1143-1168.	0.9	22
26	Increased P2X ₇ expression in the gastrointestinal tract and skin in a humanised mouse model of graft-versus-host disease. Clinical Science, 2020, 134, 207-223.	1.8	19
27	Functional significance of P2RX ₇ polymorphisms associated with affective mood disorders. Journal of Psychiatric Research, 2010, 44, 1116-1117.	1.5	14
28	The P2X ₇ receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice. Purinergic Signalling, 2017, 13, 405-415.	1.1	11
29	A P2RX ₇ single nucleotide polymorphism haplotype promotes exon 7 and 8 skipping and disrupts receptor function. FASEB Journal, 2020, 34, 3884-3901.	0.2	10
30	The Effect of Antidepressants on Mesenchymal Stem Cell Differentiation. Journal of Bone Metabolism, 2018, 25, 43.	0.5	9
31	Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. International Journal of Molecular Sciences, 2021, 22, 8343.	1.8	9
32	CXCR4 but not CXCR3 expression correlates with lymphocyte counts in B-cell chronic lymphocytic leukemia. Annals of Hematology, 2004, 83, 326-327.	0.8	7
33	Quantitative real-time PCR eliminates false-positives in colony screening PCR. Journal of Microbiological Methods, 2014, 96, 99-100.	0.7	4
34	Radiotherapy for breast cancer associated with a cutaneous presentation of systemic mastocytosis—a case report and literature review. Journal of Surgical Case Reports, 2018, 2018, rjy317.	0.2	4
35	Scurvy. Mayo Clinic Proceedings, 2019, 94, 2594-2597.	1.4	4
36	Clinical Impact of Unregulated Terminal Complement Activity in Never-Transfused Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2009, 114, 4029-4029.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Quiz Page January 2016. American Journal of Kidney Diseases, 2016, 67, A18-A21.	2.1	2
38	Differential Levels of mRNAs in Normal B Lymphocytes, Monoclonal B Lymphocytosis and Chronic Lymphocytic Leukemia Cells from the Same Family Identify Susceptibility Genes. Oncology and Therapy, 2021, 9, 621-634.	1.0	1
39	Chronic leukaemias in the community. Australian Prescriber, 2020, 43, 126-130.	0.5	1
40	Intracerebral hemorrhage after thrombolytic therapy managed with ventricular drainage. Journal of Clinical Neuroscience, 2007, 14, 898-900.	0.8	0
41	Multiple Intraabdominal Purulent Collections Demonstrated on FDG PET/CT in Staging of Non-Hodgkin Lymphoma. Clinical Nuclear Medicine, 2012, 37, 210-213.	0.7	0
42	In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial. Blood, 2019, 134, 4247-4247.	0.6	0
43	Inhibiting the P2Y13 receptor reduces IL-33 and HMGB1 lung concentrations and inflammatory cell infiltration in a murine model of asthma. Purinergic Signalling, 2022, , 1.	1.1	0